Brean Capital Starts Synta Pharma. (SNTA) at Buy, Sees Upcoming Catalysts for Ganetespib
Tweet Send to a Friend
Brean Capital initiates coverage on Synta Pharma. (NASDAQ: SNTA) with a Buy. PT $12.00 saying they expect several important catalysts ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
